HAYWARD, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced today that Gary S. Titus, Kosan’s Senior Vice President and Chief Financial Officer, will present at the Credit Suisse Healthcare Conference in Phoenix at the Arizona Biltmore Resort on Friday, November 17, 2006 at 11:00 a.m. MST. A live webcast of the presentation can be accessed through http://w.on24.com/r.htm?e=31766&s=1&k=8F1623620F7CB1E1BFEF988B99B0DDFC
Interested parties may also access a live webcast of the presentation by visiting the “Events Calendar” page under the “Investors/Press” tab on Kosan’s website at http://www.kosan.com . A recorded replay of the presentation will be available for two weeks.
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan’s proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) and HER2-positive metastatic breast cancer. In addition, intravenous and oral formulations of Kosan’s second-generation Hsp90 inhibitor, alvespimycin (KOS- 1022), are being evaluated in Phase 1 clinical trials.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-862 is currently being studied in a Phase 2 single-agent clinical trial in patients with HER2-positive metastatic breast cancer, as well as a Phase 2 combination trial with Herceptin(R). KOS-1584, a second candidate designed to improve pharmacokinetics, is in Phase 1 clinical trials in patients with solid tumors. Kosan’s epothilone program is partnered with Roche through a global development and commercialization agreement.
For additional information on Kosan Biosciences, please visit the company’s website at www.kosan.com.
NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.
Kosan Biosciences Incorporated
CONTACT: Gary S. Titus, Chief Financial Officer, +1-510-731-5373, ortitus@kosan.com, or Jane Green, +1-510-731-5335, or mobile,+1-415-652-4819, or green@kosan.com
Web site: http://www.kosan.com/
